AASLD – The Liver Meeting 2020 The Liver Meeting 2020 bulletinRead our AASLD news bulletin in English, Spanish, Russian, French and Portuguese. Abigail Adams of the Task Force for Global Health, Atlanta (bottom right) and the Liver Meeting Hepatitis C Epidemiology Panel © The Liver Meeting Digital Experience™ 2020EpidemiologyFew countries will meet 2020 target for reducing viral hepatitis deaths. Image: Helen Sushitskaya/Shutterstock.comMother-to-child HBV transmissionTenofovir alafenamide prevents mother-to-child hepatitis B virus transmission. infohep news Experimental treatments for NASH/NAFLD Semaglutide alone or in combination regimens shows promise for NASH Liz Highleyman / 18 December 2020 Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ... Experimental treatments for NASH/NAFLD Lanifibranor improves NASH in 24-week trial Keith Alcorn / 18 December 2020 Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ... Experimental treatments for NASH/NAFLD Efruxifermin improves liver fat and fibrosis in people with NASH Keith Alcorn / 15 December 2020 Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ... Epidemiology Few countries will meet 2020 target for reducing viral hepatitis deaths Keith Alcorn / 24 November 2020 Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of direct-acting antiviral treatment, according to analyses of ... Antiviral therapy Some hepatitis B patients can safely stop antivirals Liz Highleyman / 24 November 2020 Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ... Finance, funding & health economics Can investment in hepatitis C treatment be cost saving? Keith Alcorn / 24 November 2020 Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate lower drug prices, a study presented online at this ... Mother to child Tenofovir alafenamide prevents mother-to-child hepatitis B virus transmission Liz Highleyman / 20 November 2020 Tenofovir alafenamide (TAF; Vemlidy) is highly effective at preventing transmission of hepatitis B virus (HBV) from mothers with a high viral load to their infants, according to a pair of studies presented ... Monitoring response to treatment Minimal monitoring of hepatitis C treatment is safe and effective Keith Alcorn / 17 November 2020 Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at the online AASLD Liver Meeting. The study was ... New and experimental treatments for hepatitis B NASVAC therapeutic vaccine may lead to functional cure of hepatitis B Liz Highleyman / 17 November 2020 NASVAC, an experimental therapeutic vaccine that targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen levels and several study participants achieved a functional cure after ... Coronavirus Fatty liver greatly increases vulnerability to COVID-19 in obese people Keith Alcorn / 16 November 2020 Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for SARS-CoV-2 shows. Obesity alone did not increase the risk ... View more > Editors' picks from other sources Treatment for people who use drugs State Policies Create Barriers to Hepatitis C Elimination Hep Mag / 17 November 2020 View more > Other pages in this section Latest news All the news Conference news Email bulletin archive